Skip to main content
. 2017 Jul 29;8(41):70317–70331. doi: 10.18632/oncotarget.19688

Figure 7. BiVax/IL2Cx combination show better therapeutic antitumor effects.

Figure 7

RIP-gp mice were inoculated s.c. with B16F10gp33-41 melanoma cells (3 × 105 cells/mouse). After 8 days mice received pam-gp33-41 BiVax and 9 days later (17 days after tumor inoculation) they were boosted with either pam-gp33-41 BiVax, pam-gp33-41 TriVax, pam-gp33-41 TriVax+αPD-L1 or pam-gp33-41 BiVax/IL2Cx. αPD-L1 mAb was administered i.p. on days 17, 19 and 21. A control group was primed with pam-Ova257-264 BiVax and 9 days later boosted with pam-Ova257-264 TriVax+αPD-L1 mAb. (A) Mean tumor sizes and (B) overall survival of tumor-bearing mice. (C) Blood glucose levels in individual mice (each symbol) for each group. (D) Percentages of Kb and Db tetramer+ CD8 T cells for each individual mouse in the blood at day 30 after tumor inoculation. Results presented for individual mice (each symbol) with the mean ± SD for each group. (*p<0.05, ****p<0.0001, ns: not significant).